الفهرس 
Bone complications after renal transplantationOnly 14 pages are availabe for public view
 |  | from | 125 |  |  |
| | | from | 125 | | |
Abstract
The goal when treating patient with end stage renal disease is to
increase patient survival and to provide better quality of life and to date
this could be achieved by kidney transplantation. Special problems
associated with kidney transplantation were identified and documented
and this is an essential step towards improved graft function and patient
survival. Post transplanatation hip AVN is one of these problems which
need special concern.
The present work was designed to evaluate posttransplanatation
hip AVN regarding; incidence, risk factors different modalities of
treatment.
This study comprise 40 patients who received their graft between
march, 1976 and December, 2005 and developed hip AVN post
transplantation. They were compared with healthy 80 kidney transplant
recipients.
from our study we conclude the following:
1- The incidence of posttransplant hip AVN among our recipients was
2.24%.
2- The most important risk factors for the development of
posttransplantaion hip AVN were;
a- Genetic predisposition specifically HLA A9, HLAB35 AND DR
B15.
b- Immunosuppressive drugs specially, corticosteroids and sirolimus
c- Overweight with BMI more than 26
d- Hypercholesterolemia.
_________________________________Summary & Conclusion______
٩٠
3- The appropriate treatment of early hip AVN is hip decompression
while in advanced cases sooner or later hip replacement will be
needed.
4-Hip AVN has no impact on graft and patient survival.
Finally, we can recommend the following:
1- ESRD patients with genetic loci HLA A9, HLAB35 AND DR B15
and willing to have a renal allograft may be eligible to receive steroid
and sirolimus free immunosuppressive regimen in order to avoid
development of hip AVN.
2- Kidney transplant recipients should be advised to maintain ideal body
weight and avoid obesity to save their hip joint from AVN.
3- Kidney transplant recipients should pay special attention to control
lipid profile and hypercholesterolemia.